Jade Biosciences Inc. (JBIO)
NASDAQ: JBIOHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
JBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $875.74M
- EPS (TTM)
- -$1.97
- Dividend yield
- None
- Ex-dividend date
- Apr 29, 2025
- 52-week range
- 8.36 – 28.00
- Day range
- 13.08 – 14.14
- Volume / Avg
- 950.77K / 887.66K
- Beta
- —
- Shares outstanding
- 63.60M
52-week range
JBIO stock today
On Oct 7, JBIO ended the session at $13.77, adding $0.36 (2.68%), versus the S&P 500's 0.22% decline. At this level, JBIO sits in the middle of its 52-week range of $8.36 to $28.00: 50.8% below the high, set on Apr 27, 2026 and 64.7% above the low. JBIO is down 10.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 52.3%.
Jade Biosciences has posted a net loss over the last twelve months (EPS of -$1.97), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Jade Biosciences
Company profileJade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Tom Frohlich
- Headquarters
- Waltham, MA
- Employees
- 55
- IPO year
- 2021
- Website
- jadebiosciences.com
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$50.13+264.05%
- Strong buy 0
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $2.40
- Ex-dividend date
- Apr 29, 2025
Jade Biosciences peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRVSCorvus Pharmaceuticals Inc. | 10.41 | -1.42% | $875.70M | vs JBIO |
| ALMSAlumis Inc. | 6.77 | -2.31% | $876.28M | vs JBIO |
| ODTXOdyssey Therapeutics Inc. | 18.08 | -0.28% | $868.90M | vs JBIO |
| GLUEMonte Rosa Therapeutics Inc. | 10.17 | +3.04% | $867.64M | vs JBIO |
| RIGLRigel Pharmaceuticals Inc. | 47.99 | +4.08% | $896.45M | vs JBIO |
| SLBTSL Science Holding Limited | 1.51 | -0.66% | $846.75M | vs JBIO |
| ANLAdlai Nortye Group Ltd. ADR | 14.05 | -2.84% | $904.79M | vs JBIO |
| ARDXArdelyx Inc. | 3.26 | -1.51% | $841.69M | vs JBIO |
Indexes, lists and sector
Jade Biosciences stock FAQ
What is Jade Biosciences's stock price today?
JBIO last traded at $13.77 as of Oct 7, 4:00 PM EDT, up 2.68% on the day. Prices are delayed at least 15 minutes.
Does Jade Biosciences pay a dividend?
Yes. Jade Biosciences pays $0.00 per share annually. The most recent dividend of $2.40 had an ex-dividend date of Apr 29, 2025.
Who is Jade Biosciences's CEO?
Mr. Tom Frohlich is the chief executive officer of Jade Biosciences Inc., which has about 55 employees.
Has JBIO ever split its stock?
Yes. The most recent JBIO stock split was a 1-for-35 split on Apr 29, 2025.
What is the JBIO 52-week high?
The 52-week high for JBIO is $28.00 and the 52-week low is $8.36. The stock is currently 50.8% below its high.